<DOC>
	<DOCNO>NCT00651807</DOCNO>
	<brief_summary>This trial conduct evaluate effect etonogestrel comparison placebo : - prostate volume urinary complaint ; - urinary flow urinary volume bladder voiding ; - progression disease ; - sexual function , well-being urinary complaints-related Quality Life . In addition safety way drug absorb excrete body analyze .</brief_summary>
	<brief_title>A Trial Investigate Effectiveness Safety Org 3236 ( Etonogestrel ) Tablets Men With Urinary Complaints Suggestive Benign Enlargement Prostate ( 304001 ) ( P05806 )</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<mesh_term>Etonogestrel</mesh_term>
	<mesh_term>Desogestrel</mesh_term>
	<criteria>Signed write informed consent , obtain screening evaluation ; Men diagnose LUTS suggestive BPH : Baseline IPSS score = 12 ( moderate severe ) ; Prostate volume = 40 mL &lt; 100 mL ( base TRUS ) ; Peak urinary flow rate = 15 mL/s void volume =125 mL Age least 50 old 80 year screen PSA &lt; 10 ng/mL exclusion prostate cancer satisfaction investigator ( e.g . biopsy ) A post void residual volume &gt; 250 mL Use drug interfere efficacy assessment within two week six month prior start treatment ( depend drug ) Acute urinary retention within past 12 month History surgery BPH , include minimally invasive procedure Presence urinary tract infection Presence history ( subclinical ) prostate cancer , bladder cancer , urethral stricture , pelvic irradiation Cardiac cerebrovascular event within past six month Presence history neurological disease associate primary bladder dysfunction Presence history liver/renal disease disturbance liver/renal function fail return normal Clinically relevant abnormal laboratory result judge ( sub ) investigator</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>